David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 18,547 shares at $296.44 ($5.5M) on 2023-02-13, disclosed to the SEC on 2023-02-14.
Seasonal sale ($5.5M) by EVP, Global Research and CSO — this insider has traded VRTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $294.33 | 3,461 | $1.0M | 18.4% |
| 2 | $296.44 | 245 | $73K | 1.3% |
| 3 | $296.44 | 245 | $73K | 1.3% |
| 4 | $298.26 | 5,990 | $1.8M | 32.3% |
| 5 | $298.47 | 2,160 | $645K | 11.7% |
| 6 | $298.47 | 2,160 |
| $645K |
| 11.7% |
| 7 | $299.36 | 1,893 | $567K | 10.3% |
| 8 | $299.36 | 1,893 | $567K | 10.3% |
| 9 | $300.23 | 500 | $150K | 2.7% |
| Total | $297.81 avg | 18,547 | $5.5M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |